Belite Bio Announces $15 Million Registered Direct Offering

SAN DIEGO, August 7, 2025 — Leads & Copy — Belite Bio, Inc. (BLTE) has announced a securities purchase agreement for 230,770 American Depositary Shares (ADSs) and warrants to purchase the same amount of ADSs at $65 per ADS and accompanying warrant, in a registered direct offering. The offering should result in gross proceeds of about $15 million, before deducting offering expenses, with potential for another $15 million if the five-year warrants issued in the offering are exercised.

The closing is expected on or about August 8, 2025, pending customary conditions. The funds will be used for working capital and general corporate purposes.

Titan Partners Group, a division of American Capital Partners, is the sole placement agent.

The offering is made via a shelf registration statement on Form F-3, previously filed with the SEC and declared effective on January 27, 2025. The prospectus supplement is available on the SEC’s website and can be obtained from Titan Partners Group LLC.

Jennifer Wu / ir@belitebio.com

Julie Fallon / belite@argotpartners.com

Source: Belite Bio, Inc

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.